Blar i forfatter "Akaberi, Dario"

Viser treff 1-2 av 2

    • Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway 

      Kjellin, Midori; Kileng, Hege; Akaberi, Dario; Palanisamy, Navaneethan; Duberg, Ann-Sofi; Danielsson, Astrid; Kristiansen, Magnhild Gangsøy; Nöjd, Johan Edvin; Aleman, Soo; Gutteberg, Tore Jarl; Goll, Rasmus; Lannergård, Anders; Lennerstrand, Johan (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-08-19)
      <i>Background</i>: The NS5A resistance-associated substitution (RAS) Y93H is found quite frequently (5–10%) at baseline in direct-acting antiviral agents (DAA) treatment-naïve genotype (GT) 3a patients when studied by the population-sequencing method (cut-off 20%). This RAS may impair HCV DAA treatment response, since it possesses a high fold <i>in vitro</i> resistance to daclatasvir (DCV) and ...

    • Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy 

      Kileng, Hege; Kjellin, Midori; Akaberi, Dario; Bergfors, Assar; Duberg, Ann-Sofi; Wesslen, Lars; Danielsson, Astrid; Kristiansen, Magnhild Gangsøy; Gutteberg, Tore Jarl; Goll, Rasmus; Lannergård, Anders; Lennerstrand, Johan (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-05)
      <i>Objectives</i>: Resistance-associated substitutions (RASs) may impair treatment response to direct-acting antivirals (DAA) in hepatitis C virus (HCV) treatment. We investigated the effects of baseline NS3-RASs (Q80K and R155K) and clinically relevant NS5A-RASs in patients with HCV genotype (GT) 1a infection on treatment outcome, with or without resistance-based DAA-treatment. This multi-center ...